Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse comparison of two treatment schedules

• Published in: Digestive diseases and sciences Vol. 46; no. 11; pp. 2389 - 2395
• Main Authors: ROSSINI, Angelo, ARTINI, Marco, LEVRERO, Massimo, ALMERIGHI, Cristiana, MASSARI, Marco, BIASI, Luciano, RADAELI, Enrico, CARIANI, Elisabetta
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 01.11.2001; Springer Nature B.V
• Subjects: Alanine Transaminase - blood; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Biological and medical sciences; Drug Administration Schedule; Female; Hepacivirus - isolation & purification; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Human viral diseases; Humans; Infectious diseases; Interferon alpha-2; Interferon-alpha - administration & dosage; Interferon-alpha - therapeutic use; Male; Medical sciences; Middle Aged; Predictive Value of Tests; Recombinant Proteins; RNA, Viral - blood; Sensitivity and Specificity; Time Factors; Viral diseases; Viral hepatitis; Human; Immune response; RNA; Treatment efficiency; Cytokine; Genotype; Immunomodulator; Infection; Virus; Chemotherapy; Randomization; Viral disease; Interferon inducer; Antiviral; Flaviviridae; Predictive factor; Hepatitis C virus; Hepacivirus; Viral load
• ISSN: 0163-2116; 1573-2568
• DOI: 10.1023/a:1012303315214

The aim of this study was to analyze of HCV kinetics during interferon treatment administered daily or three times weekly. Seventy-seven naive patients were randomized to two treatment courses starting with four weeks of high-dose interferon administered daily or three times weekly. Twenty-two patients (28.6%) achieved end-of-treatment response and nine (11.7%, four of whom received daily induction) sustained response. The initial decline of viral load was sharper in patients receiving daily induction, but the rates of early RNA clearance were independent of treatment schedule, being higher in patients with genotype non-1. Detectable HCV RNA during treatment predicted nonresponse more significantly than high pretreatment viral load or genotype 1. HCV RNA at week 2 was the best predictor (100% sensitivity in patients receiving daily induction). In conclusion, daily induction increased the HCV decline slope, but not the rate of virological response. HCV RNA at week 2 reliably identified nonresponders.